Connect Biopharma (NASDAQ:CNTB) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Connect Biopharma (NASDAQ:CNTB) from a hold rating to a sell rating in a report published on Saturday.

Several other equities research analysts have also recently weighed in on CNTB. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Connect Biopharma in a research report on Monday, May 4th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Connect Biopharma in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Connect Biopharma Trading Down 4.0%

CNTB opened at $2.38 on Friday. Connect Biopharma has a twelve month low of $0.72 and a twelve month high of $3.82. The company has a 50-day simple moving average of $2.73 and a 200 day simple moving average of $2.52. The company has a quick ratio of 3.74, a current ratio of 3.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $149.84 million, a price-to-earnings ratio of -2.07 and a beta of -0.21.

Connect Biopharma (NASDAQ:CNTB) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.05). The company had revenue of $0.02 million for the quarter. Analysts predict that Connect Biopharma will post -0.96 EPS for the current fiscal year.

Insider Activity at Connect Biopharma

In related news, Director James Huang bought 1,160,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average price of $3.45 per share, with a total value of $4,002,000.00. Following the completion of the acquisition, the director owned 13,160,000 shares of the company’s stock, valued at $45,402,000. The trade was a 9.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 22.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Knott David M Jr lifted its holdings in shares of Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after acquiring an additional 187,835 shares during the last quarter. Simplify Asset Management Inc. bought a new position in shares of Connect Biopharma in the first quarter worth about $135,000. Perceptive Advisors LLC bought a new position in shares of Connect Biopharma in the fourth quarter worth about $2,235,000. Millennium Management LLC bought a new position in shares of Connect Biopharma in the fourth quarter worth about $133,000. Finally, Royal Bank of Canada bought a new position in shares of Connect Biopharma in the fourth quarter worth about $114,000. Institutional investors own 58.72% of the company’s stock.

Key Connect Biopharma News

Here are the key news stories impacting Connect Biopharma this week:

• Neutral Sentiment: HC Wainwright reiterated that Connect Biopharma is still expected to post losses for the foreseeable future, with updated EPS forecasts remaining deeply negative across 2026-2030. This keeps attention on execution and cash burn rather than near-term earnings growth.
• Neutral Sentiment: The company is also expected to report quarterly earnings soon, which could add volatility if results or guidance differ from expectations. Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: An article questioning whether companies like Connect Biopharma are “quite risky” may reinforce investor caution, though it does not appear to introduce a new company-specific catalyst. Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky
• Negative Sentiment: HC Wainwright lowered FY2026 EPS estimates to a larger loss, and also trimmed forecasts for FY2027, FY2028, FY2029, and FY2030, signaling weaker longer-term earnings expectations.
• Negative Sentiment: Near-term estimates for Q2 and Q3 2026 were also reduced, suggesting analysts see limited progress in the company’s operating outlook over the next few quarters.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.